أرسل هذا في رسالة قصيرة: Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

  ______    _____     _____    _    _    __   _   
 /_   _//  |  ___||  |__  //  | || | || | || | || 
   | ||    | ||__      / //   | || | || | '--' || 
  _| ||    | ||__     / //__  | \\_/ || | .--. || 
 /__//     |_____||  /_____||  \____//  |_|| |_|| 
 `--`      `-----`   `-----`    `---`   `-`  `-`